Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01275 (
glucagon
)
26,492
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Histomorphological and functional alterations in pancreatic islet composition directly correlate with hyperglycemia severity. Progressive deterioration of metabolic control in subjects suffering from type 2 diabetes is predominantly caused by impaired beta-cell functionality. The glutaredoxin system is supposed to wield protective properties for beta-cells. Therefore, we sought to identify a correlation between the structural changes observed in diabetic pancreatic islets with altered
glutaredoxin 5
expression, in order to determine an underlying mechanism of beta-cell impairment. Islets of db/db mice presenting with uncontrolled diabetes were assessed in terms of morphological structure and insulin,
glucagon
, and
glutaredoxin 5
expression. MIN6 cell function and
glutaredoxin 5
expression were analyzed after exposure to oleic acid and hypoxia. Islets of diabese mice were marked by typical remodeling and distinct reduction of, and shifts, in localization of
glutaredoxin 5
-positive cells. These islets featured decreased
glutaredoxin 5
as well as insulin and
glucagon
content. In beta-cell culture,
glutaredoxin 5
protein and mRNA expression were decreased by hypoxia and oleic acid but not by leptin treatment. Our study demonstrates that
glutaredoxin 5
expression patterns are distinctively altered in islets of rodents presenting with uncontrolled diabesity.
In vitro
, reduction of islet-cell
glutaredoxin 5
expression was mediated by hypoxia and oleic acid. Thus,
glutaredoxin 5
-deficiency in islets during diabetes may be caused by lipotoxicity and hypoxia.
...
PMID:Distinct Shift in Beta-Cell Glutaredoxin 5 Expression Is Mediated by Hypoxia and Lipotoxicity Both
In Vivo
and
In Vitro
. 2959 51